Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Pneumonia therapeutics industry 3600 synopsis, 2015 - 2026
2.1.1. Business trends
2.1.2. Drug class trends
2.1.3. Age group trends
2.1.4. Infection type trends
2.1.5. Distribution channel trends
2.1.6. Regional trends
Chapter 3. Pneumonia Therapeutics Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2015 - 2026
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Surging cases of pneumonia across the globe
3.3.1.2. Rising number of ongoing clinical trials for vaccine development and drug molecules
3.3.1.3. Increasing funding opportunities in R&D for new product development
3.3.1.4. Presence of various manufacturers in developed economies
3.3.2. Industry pitfalls and challenges
3.3.2.1. Low treatment rates in developing economies
3.4. Growth potential analysis
3.4.1. By drug class
3.4.2. By age group
3.4.3. By infection type
3.4.4. By distribution channel
3.5. COVID-19 impact analysis
3.6. Product pipeline analysis
3.7. Porter’s analysis
3.8. PESTEL Analysis
Chapter 4. Pneumonia Therapeutics Market, By Drug Class
4.1. Key segment trends
4.2. Antibacterial drugs
4.2.1. Antibacterial drugs market, by region, 2015 - 2026, (USD Million)
4.2.2. Macrolide
4.2.2.1. Macrolide market, by region, 2015 - 2026, (USD Million)
4.2.3. Quinolones
4.2.3.1. Quinolones market, by region, 2015 - 2026, (USD Million)
4.2.4. Others
4.2.4.1. Others market, by region, 2015 - 2026, (USD Million)
4.3. Antiviral drugs
4.3.1. Antiviral drugs market, by region, 2015 - 2026, (USD Million)
4.4. Antifungal drugs
4.4.1. Antifungal drugs market, by region, 2015 - 2026, (USD Million)
Chapter 5. Pneumonia Therapeutics Market, By Age Group
5.1. Key segment trends
5.2. Pediatric
5.2.1. Pediatric market by region, 2015 - 2026 (USD Million)
5.3. Adult
5.3.1. Adult market, by region, 2015 - 2026, (USD Million)
5.4. Geriatric
5.4.1. Geriatric market by region, 2015 - 2026 (USD Million)
Chapter 6. Pneumonia Therapeutics Market, By Application
6.1. Key segment trends
6.2. Pediatric
6.2.1. Pediatric pneumonia therapeutics market, by region, 2015 - 2026, (USD Million)
6.3. Adult
6.3.1. Adult pneumonia therapeutics market, by region 2015 - 2026, (USD Million)
6.4. Geriatric
6.4.1. Geriatric pneumonia therapeutics market, by region 2015 - 2026, (USD Million)
6.5. Veterinary
6.5.1. Veterinary pneumonia therapeutics market, by region 2015 - 2026, (USD Million)
Chapter 7. Pneumonia Therapeutics Market, By Infection Type
7.1. Key segment trends
7.2. Hospital-acquired pneumonia (HAP)
7.2.1. Hospital-acquired pneumonia (HAP) market, by region, 2015 - 2026, (USD Million)
7.3. Community-acquired pneumonia (CAP)
7.3.1. Community-acquired pneumonia (CAP) market, by region, 2015 - 2026, (USD Million)
7.4. Ventilator-associated pneumonia (VAP)
7.4.1. Ventilator-associated pneumonia (VAP) market, by region, 2015 - 2026, (USD Million)
Chapter 8. Pneumonia Therapeutics Market, By Distribution Channel
8.1. Key segment trends
8.2. Hospital pharmacies
8.2.1. Hospital pharmacies market, by region, 2015 - 2026, (USD Million)
8.3. Retail pharmacies
8.3.1. Retail Pharmacies market, by region, 2015 - 2026, (USD Million)
8.4. Online pharmacies
8.4.1. Online pharmacies market, by region, 2015 - 2026, (USD Million)
Chapter 9. Pneumonia Therapeutics Market, By Region
9.1. Key regional trends
9.2. North America
9.2.1. North America pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.2.2. North America pneumonia therapeutics market, By drug class, 2015 - 2026 (USD Million)
9.2.2.1. North America pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.2.3. North America pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.2.4. North America pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.2.5. North America pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.2.6. U.S.
9.2.6.1. U.S. pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.2.6.1.1. U.S. pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.2.6.2. U.S. pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.2.6.3. U.S. pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.2.6.4. U.S. pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.2.7. Canada
9.2.7.1. Canada pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.2.7.1.1. Canada pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.2.7.2. Canada pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.2.7.3. Canada pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.2.7.4. Canada pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3. Europe
9.3.1. Europe pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.3.2. Europe pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.2.1. Europe pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.3. Europe pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.4. Europe pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.5. Europe pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.6. Germany
9.3.6.1. Germany pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.6.1.1. Germany pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.6.2. Germany pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.6.3. Germany pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.6.4. Germany pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.7. UK
9.3.7.1. UK pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.7.1.1. UK pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.7.2. UK pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.7.3. UK pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.7.4. UK pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.8. France
9.3.8.1. France pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.8.1.1. France pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.8.2. France pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.8.3. France pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.8.4. France pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.9. Italy
9.3.9.1. Italy pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.9.1.1. Italy pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.9.2. Italy pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.9.3. Italy pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.9.4. Italy pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.10. Spain
9.3.10.1. Spain pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.10.1.1. Spain pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.10.2. Spain pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.10.3. Spain pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.10.4. Spain pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.11. Russia
9.3.11.1. Russia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.11.1.1. Russia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.11.2. Russia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.11.3. Russia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.11.4. Russia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.12. Sweden
9.3.12.1. Sweden pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.12.1.1. Sweden pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.12.2. Sweden pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.12.3. Sweden pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.12.4. Sweden pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.13. Finland
9.3.13.1. Finland pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.13.1.1. Finland pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.13.2. Finland pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.13.3. Finland pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.13.4. Finland pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.4.2. Asia Pacific pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.2.1. Asia Pacific pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.3. Asia Pacific pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.4. Asia Pacific pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.5. Asia Pacific pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.6. Japan
9.4.6.1. Japan pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.6.1.1. Japan pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.6.2. Japan pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.6.3. Japan pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.6.4. Japan pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.7. China
9.4.7.1. China pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.7.1.1. China pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.7.2. China pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.7.3. China pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.7.4. China pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.8. India
9.4.8.1. India pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.8.1.1. India pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.8.2. India pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.8.3. India pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.8.4. India pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.9. Australia
9.4.9.1. Australia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.9.1.1. Australia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.9.2. Australia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.9.3. Australia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.9.4. Australia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.10. Philippines
9.4.10.1. Philippines pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.10.1.1. Philippines pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.10.2. Philippines pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.10.3. Philippines pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.10.4. Philippines pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5. Latin America
9.5.1. Latin America pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.5.2. Latin America pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.2.1. Latin America pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.3. Latin America pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.4. Latin America pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.5. Latin America pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.6. Brazil
9.5.6.1. Brazil pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.6.1.1. Brazil pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.6.2. Brazil pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.6.3. Brazil pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.6.4. Brazil pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.7. Mexico
9.5.7.1. Mexico pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.7.1.1. Mexico pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.7.2. Mexico pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.7.3. Mexico pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.7.4. Mexico pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.8. Chile
9.5.8.1. Chile pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.8.1.1. Chile pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.8.2. Chile pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.8.3. Chile pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.8.4. Chile pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.9. Peru
9.5.9.1. Peru pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.9.1.1. Peru pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.9.2. Peru pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.9.3. Peru pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.9.4. Peru pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.10. Argentina
9.5.10.1. Argentina pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.10.1.1. Argentina pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.10.2. Argentina pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.10.3. Argentina pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.10.4. Argentina pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6. MEA
9.6.1. MEA pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.6.2. MEA pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.2.1. MEA pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.3. MEA pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.4. MEA pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.5. MEA pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6.6. South Africa
9.6.6.1. South Africa pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.6.1.1. South Africa pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.6.2. South Africa pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.6.3. South Africa pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.6.4. South Africa pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6.7. Saudi Arabia
9.6.7.1. Saudi Arabia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.7.1.1. Saudi Arabia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.7.2. Saudi Arabia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.7.3. Saudi Arabia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.7.4. Saudi Arabia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6.8. UAE
9.6.8.1. UAE pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.8.1.1. UAE pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.8.2. UAE pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.8.3. UAE pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.8.4. UAE pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6.9. Israel
9.6.9.1. Israel pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.9.1.1. Israel pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.9.2. Israel pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.9.3. Israel pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.9.4. Israel pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
Chapter 10. Company Profiles
10.1. Strategy Dashboard, 2019
10.2. Abbott Laboratories
10.2.1. Business Overview
10.2.2. Financial data
10.2.3. Product landscape
10.2.4. Strategic outlook
10.2.5. SWOT analysis
10.3. Allergan, Inc.
10.3.1. Business overview
10.3.2. Financial data
10.3.3. Product landscape
10.3.4. Strategic outlook
10.3.5. SWOT analysis
10.4. AstraZeneca plc.
10.4.1. Business overview
10.4.2. Financial data
10.4.3. Product landscape
10.4.4. Strategic outlook
10.4.5. SWOT analysis
10.5. Bayer AG
10.5.1. Business overview
10.5.2. Financial Data
10.5.3. Product landscape
10.5.4. Strategic outlook
10.5.5. SWOT analysis
10.6. Cipla Inc.
10.6.1. Business overview
10.6.2. Financial data
10.6.3. Product landscape
10.6.4. SWOT analysis
10.7. GlaxoSmithKline plc.
10.7.1. Business overview
10.7.2. Financial data
10.7.3. Product landscape
10.7.4. Strategic outlook
10.7.5. SWOT analysis
10.8. Lupin Pharmaceuticals, Inc.
10.8.1. Business overview
10.8.2. Financial data
10.8.3. Product landscape
10.8.4. SWOT analysis
10.9. Merck & Co., Inc.
10.9.1. Business overview
10.9.2. Financial data
10.9.3. Product landscape
10.9.4. SWOT analysis
10.10. Mylan N.V.
10.10.1. Business overview
10.10.2. Financial data
10.10.3. Product landscape
10.10.4. SWOT analysis
10.11. Novartis AG
10.11.1. Business overview
10.11.2. Financial data
10.11.3. Product landscape
10.11.4. Strategic outlook
10.11.5. SWOT analysis
10.12. Pfizer Inc.
10.12.1. Business overview
10.12.2. Financial data
10.12.3. Product landscape
10.13. Sanofi S.A.
10.13.1. Business overview
10.13.2. Financial data
10.13.3. Product landscape
10.13.4. SWOT analysis
